Mesoblast's Ryoncil® Shows 84% Survival in Pediatric SR-aGvHD Real-World Data

Event summary

  • 84% survival rate observed in 25 pediatric SR-aGvHD patients treated with Ryoncil® for 28 days post-FDA approval in March 2025.
  • 4 patients who did not complete treatment died within 28 days due to severe SR-aGvHD.
  • 45 transplant centers onboarded, targeting 64 centers covering 94% of U.S. transplants.
  • CMS HCPCS J-Code issuance in October 2025 boosted Ryoncil® usage under government coverage.
  • Pivotal adult SR-aGvHD trial with BMT-CTN expected to begin enrollment this quarter.

The big picture

Mesoblast's strong real-world survival data for Ryoncil® in pediatric SR-aGvHD reinforces its leadership in cellular medicines for inflammatory diseases. The company's focus on early treatment initiation and expanding access through its patient hub and payer coverage positions it well for potential label expansion into the larger adult market. Success in this area could significantly boost its commercial prospects, particularly as it competes in the rapidly evolving cell therapy space.

What we're watching

Label Expansion
Whether Mesoblast can successfully expand Ryoncil®'s FDA approval to adult SR-aGvHD, a market three times larger than the pediatric indication.
Reimbursement Dynamics
The pace at which CMS and commercial payers adopt the HCPCS J-Code, which could significantly impact Ryoncil®'s market penetration.
Clinical Execution
How quickly Mesoblast can enroll and complete the pivotal adult SR-aGvHD trial with BMT-CTN, which is critical for label expansion.